CRISPR Therapeutics AG is a biopharmaceutical company specializing in gene editing therapies using its proprietary CRISPR/Cas9 platform. This revolutionary technology enables precise alteration of gen... CRISPR Therapeutics AG is a biopharmaceutical company specializing in gene editing therapies using its proprietary CRISPR/Cas9 platform. This revolutionary technology enables precise alteration of genomic DNA sequences to develop transformative medicines for serious diseases. The company maintains a robust portfolio of programs targeting hemoglobinopathies like sickle cell disease and beta-thalassemia with ex vivo therapies such as CASGEVY, alongside CAR T cell therapies, in vivo editing for cardiovascular conditions including CTX310 and CTX460, and type 1 diabetes. Its pipeline also advances treatments for alpha-1 antitrypsin deficiency via novel SyNTase editing and oncology applications. CRISPR Therapeutics AG focuses on both ex vivo and in vivo modalities to address unmet needs in hematology, immunology, oncology, cardiovascular, and rare genetic disorders. Founded in 2013 and headquartered in Zug, Switzerland, with key operations in Boston, the company plays a pivotal role in advancing gene-based treatments toward clinical and commercial stages in the biotechnology sector.Show lessShow more

Disclosures ESG Data Financial Data

Income Statement Balance Sheet Group Entities

Data not available

Group Entities data not yet covered for CRISPR Therapeutics

We have not yet reviewed CRISPR Therapeutics's disclosures for Group Entities data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review CRISPR Therapeutics's data?

Start your 30-day free trial to request a data review for CRISPR Therapeutics.

Start Free Trial

Legal Center Contact Us

CRISPR Therapeutics AG

Group Entities data not yet covered for CRISPR Therapeutics

Account Restricted